An Expanded Access Protocol of Intravenous Trehalose Injection 90 mg/mL Treatment of Patients with A — Suma Babu (MASSACHUSETTS GE
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative. There are two FDA-approved medications to slow ALS progression, riluzole and edaravone; their effect is modest, but addi
| Project title | An Expanded Access Protocol of Intravenous Trehalose Injection 90 mg/mL Treatment of Patients with A |
|---|---|
| Project number | 1UF1NS131791-01 |
| PI name | Suma Babu |
| Institution | MASSACHUSETTS GENERAL HOSPITAL |
| Funding mechanism | UF1 |
| Agency | NINDS |
| Award amount | $18.14M |
| Fiscal year | 2022 |
| Project start | 2022-09-28T00:00:00 |
| Project end | 2026-08-31T00:00:00 |
| Abstract | Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative. There are two FDA-approved medications to slow ALS progression, riluzole and edaravone; their effect is modest, but addi |
| Key terms | <2-Amino-6-trifluoromethoxybenzothiazole><ALS patients><Amyotrophic Lateral Sclerosis><Amyotrophic L |
$799/mo
Try GrantRadar →